All In Biotech

Drug Trial Radar · NCT07893158

A Study of Nicotine Orodispersible Tablet on Craving Relief of Male and Female Smoker Volunteers

A Randomized, Double-Blind, Fasting, Pharmacodynamic Study of Nicotine Orodispersible Tablet on Craving Relief of Male and Female Smoker Volunteers

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Oct 5, 2026

Primary completion

Oct 30, 2027

Study completion Oct 30, 2027

Sponsor

Lead sponsor
McNeil ABIndustry
Sponsor type
Industry
First posted
Oct 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the relief of momentary urge to smoke at pre-specified early post-dose time points after administration of Nic ODT compared to Placebo ODT.

Conditions

  • Smoking Cessation
  • Nicotine Replacements Therapy

Interventions

  • Nicotine Mint Oro Dispersible Tablet (Nic ODT)Drug

    Nic ODT 2.0 mg, orally

  • Placebo Oro Dispersible Tablet (Placebo ODT)Drug

    Placebo ODT, orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visual Analog Scale (VAS) score changeTime frame: 2 minutes, 1 minute, 0.75 minutes (45 seconds) and 0.5 minutes (30 seconds) after start of IP administration.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Inflamax Research DBA Cliantha Research Limited - Ontario

    Mississauga, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.